SCHEMBL4635636

SCHEMBL4635636

COC(=O)Cc1c(C)c(S(=O)(=O)c2ccc(F)cc2)c2ccccn12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 3/20 0.52
HCRTR2 O43614 3/20 0.52
ALDH1A1 P00352 6/20 0.41
MAPK1 P28482 3/20 0.41
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
POLB P06746 2/20 0.41
GAA P10253 2/20 0.41
MAPT P10636 3/20 0.40
LMNA P02545 2/20 0.40
CYP2C9 P11712 2/20 0.40
PTGDR Q13258 2/20 0.40
PTGDR2 Q9Y5Y4 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CYP3A4 P08684 1/20 0.40
KDM4E B2RXH2 3/20 0.39
HPGD P15428 2/20 0.39
HSD17B10 Q99714 2/20 0.39
HTT P42858 2/20 0.39
NPC1 O15118 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4636277 0.89 HCRTR1 (0.43) HCRTR1HCRTR2ALDH1A1MAPK1MEN1
SCHEMBL4635262 0.88 HCRTR1 (0.55) HCRTR1HCRTR2ALDH1A1MEN1KMT2A
SCHEMBL4636242 0.79 MAPT (0.45) HCRTR1HCRTR2ALDH1A1MAPK1MEN1
SCHEMBL2586103 0.79 HCRTR2 (0.58) HCRTR1HCRTR2ALDH1A1MAPK1MEN1
SCHEMBL4635350 0.78 HTR6 (0.41) HCRTR1HCRTR2ALDH1A1MAPK1MEN1
SCHEMBL2594270 0.72 HCRTR2 (0.75) HCRTR1HCRTR2ALDH1A1MEN1KMT2A
SCHEMBL4635646 0.71 ALDH1A1 (0.61) ALDH1A1MAPK1MEN1KMT2APOLB
SCHEMBL4636941 0.68 ALDH1A1 (0.42) ALDH1A1MAPK1MEN1KMT2AGAA
SCHEMBL7710901 0.67 HCRTR2 (1.00) HCRTR1HCRTR2ALDH1A1KMT2AMAPT
SCHEMBL2589640 0.67 HCRTR2 (0.55) HCRTR1HCRTR2ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080306109-A1 Indolizine Derivatives as Ligands of the Crth2 Receptor ARGENTA DISCOVERY LIMITED (GB) 2008-12-11 US disclosed
EP-1931663-A1 IMDOLIZINE DERIVATIVES AS LIGANDS OF THE CRTH2 RECEPTOR Argenta Discovery Limited (GB) 2008-06-18 EP disclosed
WO-2007031747-A1 IMDOLIZINE DERIVATIVES AS LIGANDS OF THE CRTH2 RECEPTOR ARGENTA DISCOVERY LIMITED (GB) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306109-A1 Indolizine Derivatives as Ligands of the Crth2 Receptor HRH4, HRH2, HRH3 HCRTR1 32/4885HCRTR2 7/4885ALDH1A1 3463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.